Wave Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at Jefferies Financial Group

Analysts at Jefferies Financial Group started coverage on shares of Wave Life Sciences (NASDAQ:WVE) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $26.00 price target on the stock. Jefferies Financial Group’s price target suggests a potential upside of 145.28% from the stock’s previous close.

A number of other brokerages have also commented on WVE. B. Riley upped their target price on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Mizuho increased their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Truist Financial lifted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, November 13th. Finally, StockNews.com cut shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Stock Up 2.3 %

Wave Life Sciences stock opened at $10.60 on Tuesday. The business has a 50 day moving average price of $11.90 and a two-hundred day moving average price of $11.02. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -9.55 and a beta of -1.09.

Institutional Trading of Wave Life Sciences

Several hedge funds have recently modified their holdings of WVE. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after buying an additional 856 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Wave Life Sciences by 16.6% during the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after acquiring an additional 2,073 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after acquiring an additional 2,308 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Wave Life Sciences in the fourth quarter worth about $40,000. Finally, Kraematon Investment Advisors Inc. lifted its position in shares of Wave Life Sciences by 24.3% during the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after purchasing an additional 3,885 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.